Afamitresgene Autoleucel

A personalized gene therapy that uses a patient's own T cells, which are genetically engineered to recognize and attack cancer cells expressing a specific tumor protein called MAGE-A4. The modified cells are infused back into the patient, where they seek out and destroy cancer cells while largely sparing healthy tissue.

Delivers functional copies of a gene to target cells using a viral vector, restoring expression of the deficient protein and correcting the underlying genetic defect.

Yes, Afamitresgene Autoleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.